Inhibition of NLRP3 inflammasome activation after PTL treatment was previously reported in a TBI rat model (Ding et al. 2022), in a lipopolysaccharide (LPS)-induced AD mouse model (Fan et al. 2023) and in obesity-induced inflammatory response in a mouse model (Kim et al. 2019). The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.